Clinical trials
Hematologic Neoplasms trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 12 |
| Terminated | 6 |
| Active, not recruiting | 5 |
| Unknown status | 4 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Liege | 7 |
| Kiadis Pharma | 5 |
| Janssen Research & Development, LLC | 4 |
| Novartis Pharmaceuticals | 3 |
| Bristol-Myers Squibb | 2 |
| Incyte Corporation | 2 |
| Kura Oncology, Inc. | 2 |
| Byondis B.V. | 1 |
| CSL Behring | 1 |
| Cogent Biosciences, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Neoplasms | 42 |
| Leukemia, Myeloid, Acute | 11 |
| Graft vs Host Disease | 9 |
| Leukemia | 8 |
| Myelodysplastic Syndromes | 7 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
| Leukemia, Myeloid | 4 |
| Multiple Myeloma | 4 |
| Neoplasms | 4 |
| Lymphoma, Non-Hodgkin | 3 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.